[Ⅲ治疗慢性肾脏病蛋白尿的机制：基于网络药理学的研究]
[Mechanism of Ⅲ in the treatment of proteinuria in chronic kidney disease: a network pharmacology-based study].
作者信息
Liu Huaxi, Lü Zhihao, Tian Chunyang, Ouyang Wenkun, Xiong Yifan, You Yanting, Chen Liqian, Deng Yijian, Zhao Xiaoshan, Sun Xiaomin
机构信息
School of Traditional Chinese Medicine, Southern Medical University, Guangzhou 510515, China.
First Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou 510405, China.
出版信息
Nan Fang Yi Ke Da Xue Xue Bao. 2019 Feb 28;39(2):227-234. doi: 10.12122/j.issn.1673-4254.2019.02.16.
OBJECTIVE
To identify the main active components in Ⅲ and their targets and explore the mechanism by which Ⅲ alleviates proteinuria in chronic kidney disease (CKD) based on network pharmacology.
METHODS
The active components of Ⅲ and their potential targets, along with the oral bioavailability and drug-like properties of each component were searched in the TCMSP database. The proteinuria-related targets were searched in the GeneCards database. The active component-target network was constructed using Cytoscape software, and the acquired information of the targets from ClueGO was used for enrichment analysis of the gene pathways.
RESULTS
A total of 102 active components were identified from Ⅲ. These active components acted on 126 targets, among which 69 were related to proteinuria. Enrichment analysis revealed fluid shear stress- and atherosclerosisrelated pathways as the highly significant pathways in proteinuria associated with CKD.
CONCLUSIONS
We preliminarily validated the prescription of Ⅲ and obtained scientific evidence that supported its use for treatment of proteinuria in CKD. The findings in this study provide a theoretical basis for further study of the mechanism of Ⅲ in the treatment of proteinuria in CKD.
目的
基于网络药理学，确定Ⅲ中的主要活性成分及其靶点，并探究Ⅲ缓解慢性肾脏病（CKD）蛋白尿的机制。
方法
在中药系统药理学数据库与分析平台（TCMSP）数据库中检索Ⅲ的活性成分及其潜在靶点，以及各成分的口服生物利用度和类药性质。在基因卡片（GeneCards）数据库中检索蛋白尿相关靶点。使用Cytoscape软件构建活性成分-靶点网络，并利用从ClueGO获得的靶点信息进行基因通路富集分析。
结果
从Ⅲ中总共鉴定出102种活性成分。这些活性成分作用于126个靶点，其中69个与蛋白尿相关。富集分析显示，流体剪切应力和动脉粥样硬化相关通路是与CKD相关蛋白尿中高度显著的通路。
结论
我们初步验证了Ⅲ的处方，并获得了支持其用于治疗CKD蛋白尿的科学证据。本研究结果为进一步研究Ⅲ治疗CKD蛋白尿的机制提供了理论依据。
Zotero 插件